These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 3421784

  • 1. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
    Vermue NA, Kaptein B, Tepper PG, de Vries JB, Horn AS.
    Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological profile of a chromanamine analogue (DP-6OH-3CA) of the selective presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
    Vermue NA, Dijkstra D, Horn AS.
    J Pharm Pharmacol; 1988 Aug; 40(8):574-7. PubMed ID: 2907015
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E, Tonello C, Imhof R, Scherschlicht R, da Prada M, Carruba MO.
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [Abstract] [Full Text] [Related]

  • 5. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW, Clemens JA, Hynes MD.
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [Abstract] [Full Text] [Related]

  • 6. 6,7-Dihydroxy-3-chromanamine: synthesis and pharmacological activity of an oxygen isostere of the dopamine agonist 6,7-dihydroxy-2-aminotetralin.
    Horn AS, Kaptein B, Mulder TB, de Vries JB, Wynberg H.
    J Med Chem; 1984 Oct; 27(10):1340-3. PubMed ID: 6090664
    [Abstract] [Full Text] [Related]

  • 7. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
    Mulder TB, de Vries JB, Dijkstra D, Wiechers JW, Grol CJ, Horn AS.
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):494-501. PubMed ID: 2830544
    [Abstract] [Full Text] [Related]

  • 8. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines.
    Booth RG, Baldessarini RJ, Kula NS, Gao Y, Zong R, Neumeyer JL.
    Mol Pharmacol; 1990 Jul; 38(1):92-101. PubMed ID: 1973525
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y, Fage D, Zivkovic B, Scatton B.
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP, Markstein R.
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [Abstract] [Full Text] [Related]

  • 13. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.
    Van der Weide J, De Vries JB, Tepper PG, Krause DN, Dubocovich ML, Horn AS.
    Eur J Pharmacol; 1988 Mar 01; 147(2):249-58. PubMed ID: 3130270
    [Abstract] [Full Text] [Related]

  • 14. Dose related sequence of effects induced by the DA agonist 2-(N,N-dipropyl)-amino-5,6-dihydroxytetralin.
    Doaré L, Puech AJ, Simon P.
    J Pharmacol; 1986 Mar 01; 17(1):60-4. PubMed ID: 3713199
    [Abstract] [Full Text] [Related]

  • 15. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
    Martin GE, Williams M, Pettibone DJ, Yarbrough GG, Clineschmidt BV, Jones JH.
    J Pharmacol Exp Ther; 1984 Sep 01; 230(3):569-76. PubMed ID: 6433000
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A.
    J Pharmacol Exp Ther; 1988 Dec 01; 247(3):1093-102. PubMed ID: 2905002
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT, Caprathe BW, Christoffersen CL, Corbin AE, Jaen JC, Ninteman FW, Pugsley TA, Serpa KA, Shih YH, Whetzel SZ.
    J Pharmacol Exp Ther; 1993 Sep 01; 266(3):1177-89. PubMed ID: 8103791
    [Abstract] [Full Text] [Related]

  • 18. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD, Harting J, Minck KO.
    J Pharmacol Exp Ther; 1996 Jan 01; 276(1):41-8. PubMed ID: 8558454
    [Abstract] [Full Text] [Related]

  • 19. Neuropharmacological profile of a new series of dopamine agonists: N-n-propyl-hexahydronaphthoxazines.
    Hazelhoff B, De Vries JB, Dijkstra D, Mulder TB, Timmermans PB, Wynberg H, Horn AS.
    Eur J Pharmacol; 1986 May 13; 124(1-2):93-106. PubMed ID: 3720849
    [Abstract] [Full Text] [Related]

  • 20. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan 13; 280(1):73-82. PubMed ID: 8996184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.